Overview

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the safety and tolerability of varying dose and load regimens of ISIS 301012 in people who have elevated LDL-cholesterol levels.
Phase:
Phase 2
Details
Lead Sponsor:
Kastle Therapeutics, LLC
Collaborator:
Ionis Pharmaceuticals, Inc.
Treatments:
Mipomersen